HY
Hyperfine, Inc.
HYPR · NASDAQ
$0.79 -2.63% (-$0.02)
1M -11.51%
Market Cap $66.2M
P/E Ratio -
Div. Yield -
ROE 100.30%
Bulios Fair Price
$0.53
32.9% downside
Current Price
$0.79
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HYPR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
69 /100
Cheap P/B 1.80x
P/S 4.00x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 30.80%
Rev. growth 25.79%
FCF growth N/A
Profitability
20 /100
Weak Net margin 210.75%
Op. margin 203.27%
FCF margin 166.48%
Quality
3 /100
Poor ROE 100.30%
ROA 55.32%
Asset turnover 0.26x
Debt
67 /100
Low Current ratio 6.15x
Int. coverage -55.58x
Debt/Equity 0.36x
Stability
50 /100
Moderate Rev. volatility 29.94%
EPS volatility 15.39%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HYPR
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Maria Degois Sainz
Employees
102
Headquarters
Guilford
Upcoming events
12 NOV
Earnings
Upcoming earnings report